Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in ...

Chronic myeloid leukemia (CML) is a myeloproliferative disorder which originates in a multipotent hematopoietic stem cell. 95% of the CML patients have a Philadelphia (Ph) chromosome, which results ...

Leukemia is an umbrella term for multiple different cancers that form in the blood, one such member of the leukemia family being chronic myelogenous leukemia (CML). CML is caused by a chromosomal ...

Swapping of genetic material between chromosomes 9 and 22, a chromosomal translocation called the Philadelphia chromosome, causes CML. Swapping of genetic material between chromosomes 9 and 22, a ...

The chromosomal translocation [t (9;22)] associated oncogenic fusion protein BCR-ABL drives 90% of chronic myelogenous leukemia (CML). Approximately 9,000 CML diagnosis are expected for 2023. While ...

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). A phase II study with ...

Chromosomal translocation fusion proteins contain a unique sequence at the junction of the fusion entities. The development of immunotherapies contingent on lymphocyte recognition of the junction ...

CML is a malignant clonal disorder of hematopoietic stem cells that increases not only myeloid, but also erythroid cells and platelets in the peripheral blood and induces marked myeloid hyperplasia in ...

According to the current doctrine, cancer cells develop due to mutations in genomic DNA. But could it be also caused also by faulty RNA molecules? A number of clues are pointing to this surprising ...

The burden of cancer is rising in low- and middle-income countries, yet cancer treatment requires resources that are often not available in these settings. Although management of chronic myeloid ...